Results for univariate translation from English to Maltese

various approaches were employed to derive the assumption for velocity of circulation, taking into account simple (univariate) trends as well as information available from more complex money demand models.
Ġew użati bosta metodi sabiex tinkiseb issuppożizzjoni għall-ħeffa taċ-ċirkolazzjoni, billi ġew ikkunsidrati tendenzi sempliċi (univarjati) kif ukoll informazzjoni disponibbli minn mudelli aktar kumplessi ta’ domanda għall-flus.

amt = antimyeloma therapy; ci = confidence interval; cr = complete response; d = low-dose dexamethasone; hr = hazard ratio; imwg = international myeloma working group; irac = independent response adjudication committee; m = melphalan; max = maximum; min = minimum; ne = not estimable; os = overall survival; p = prednisone; pfs = progression-free survival; pr = partial response; r = lenalidomide; rd = rd given until documentation of progressive disease; rd18 = rd given for  18 cycles; se = standard error; t = thalidomide; vgpr = very good partial response; vs = versus. a the median is based on the kaplan-meier estimate. b the 95% ci about the median. c based on cox proportional hazards model comparing the hazard functions associated with the indicated treatment arms. d the p-value is based on the unstratified log-rank test of kaplan-meier curve differences between the indicated treatment arms. e exploratory endpoint (pfs2) f the median is the univariate statistic without adjusting for censoring. g best assessment of adjudicated response during the treatment phase of the study (for definitions of each response category, data cutoff date = 24 may 2013). h data cut 24 may 2013
amt = terapija kontra l-majeloma; ci = intervall ta’ kunfidenza; cr = rispons sħiħ; d = doża baxxa ta’ dexamethasone; hr = proporzjon ta’ periklu; imwg = international myeloma working group; irac (independent response adjudication committee) = kumitat ta’ aġġudikazzjoni indipendenti dwar ir-rispons; m = melphalan; max = massimu; min = minimu; ne = mhux estimabbli; os = sopravivenza globali; p = prednisone; pfs = sopravivenza mingħajr progressjoni; pr = rispons parzjali; r = lenalidomide; rd = rd mog]ti sad-dokumentazzjoni ta’ marda progressiva; rd18 = 18-il ċiklu; se = żball standard; t = thalidomide; vgpr = rispons parzjali tajjeb ħafna; vs = kontra. a il-medjan hu bbażat fuq stima ta’ kaplan-meier. b in-95% ci madwar il-medjan. ċ ibbażat fuq il-mudell ta’ perikli proporzjonali ta’ cox li qabbel il-funzjonijiet tal-periklu assoċjati mal-parti tal-istudju indikati dwar il-kura. d il-valur p hu bbażat fuq it-test log-rank mhux stratifikat tad-differenzai fil-kurva ta’ kaplan-meier bejn il-partijiet tal-istudju indikati dwar il-kura. e punt aħħari esploratorju (pfs2) f il-medjan hu l-istatistika univarjata mingħajr aġġustament għaċ-ċensura. g l-aħjar evalwazzjoni ta’ rispons aġġudikat matul il-fażi ta’ kura tal-studju (għad-definizzjonijiet ta’ kull kategorija ta’ rispons, data tal-għeluq għad-dejta = 24 ta’ mejju, 2013). h dejta nqagħtet 24 ta’ mejju, 2013